Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764072 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT03764072 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 250 participants.
The verdict
NCT03764072, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
This study will evaluate the dose-response relationship and safety of VX-150 in treating acute pain following bunionectomy.
Interventions
- DRUG Placebo
- DRUG VX-150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2019-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03764072
The ClinicalTrials.gov registry entry for NCT03764072 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03764072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03764072 about?
NCT03764072 is a clinical study titled "A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy". This study will evaluate the dose-response relationship and safety of VX-150 in treating acute pain following bunionectomy.
What is the current status of trial NCT03764072?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2018-12-12. Estimated completion is 2019-01-25.
What interventions are being tested in trial NCT03764072?
The interventions under investigation include: Placebo (DRUG), VX-150 (DRUG).
Who is sponsoring clinical trial NCT03764072?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.